Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750205 | 0.71 | LMNA (0.36) | LMNAMAPTSMN1; SMN2 | |
| SCHEMBL3136850 | 0.60 | ALDH1A1 (0.90) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL6745548 | 0.59 | HDAC6 (0.36) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL10849623 | 0.59 | ALDH1A1 (0.86) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL13978005 | 0.58 | ALDH1A1 (0.62) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL20982737 | 0.58 | ALDH1A1 (0.62) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL3896721 | 0.58 | LMNA (1.00) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL30576980 | 0.58 | LMNA (1.00) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL27187284 | 0.58 | ALDH1A1 (0.62) | LMNAHPGDALDH1A1KDM4ETSHR | |
| SCHEMBL1534698 | 0.58 | LMNA (0.80) | LMNAHPGDALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | LMNA 4878/4885HPGD 592/4885ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.